GlassScriptPhysician profile
Leighton Harned
NPI 1649708017
$7,389.08
in general payments reported to CMS, 2019-2025
34 companies · $2,727 in 2025
The $2,727 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $20.38 · 2023: $2,162 · 2024: $2,479 · 2025: $2,727.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,367 · Education: $1.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,367.48 |
| Education | $1.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $851.23 | 2023-2025 | Tepezza, Evenity, Prolia |
| Lilly USA, LLC | $709.59 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $677.63 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $586.85 | 2023-2025 | |
| Corcept Therapeutics | $569.18 | 2023-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $537.67 | 2023-2025 | |
| Dexcom, INC. | $371.71 | 2023-2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $365.93 | 2023-2025 | Minimed 780g |
| Xeris Pharmaceuticals, INC. | $315.27 | 2022-2025 | Recorlev, Gvoke Hypopen |
| Tandem Diabetes Care, INC. | $305.23 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ibsa Pharma INC. | $255.50 | 2023-2025 | Tirosint, Licart, Tirosint |
| Boehringer Ingelheim Pharmaceuticals, INC. | $203.92 | 2023-2025 | Jardiance |
| Beta Bionics, INC. | $178.14 | 2024 | Ilet Bionic Pancreas |
| Abbott Laboratories | $151.66 | 2023-2025 | Freestyle Libre 3 |
| Antares Pharma, INC. | $148.19 | 2023-2025 | Xyosted, Nocdurna, Tlando |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $147.73 | 2023-2024 | Omnipod |
| Cequr Corporation | $125.52 | 2023-2025 | Cequr Simplicity |
| Halozyme INC | $116.78 | 2023 | |
| Ascendis Pharma Endocrinology INC | $116.58 | 2025 | Yorvipath |
| Mannkind Corporation | $76.14 | 2023 | Afrezza |
| Amneal Pharmaceuticals LLC | $72.24 | 2023-2024 | Unithroid |
| Abbvie INC. | $68.92 | 2023 | |
| Radius Health, INC. | $64.86 | 2024-2025 | |
| Madrigal Pharmaceuticals | $64.51 | 2025 | Rezdiffra |
| Sequel Med Tech, LLC | $61.47 | 2025 | Twiist |
| Kyowa Kirin, INC. | $51.42 | 2024-2025 | Crysvita |
| Neurocrine Biosciences, INC. | $36.83 | 2025 | |
| Novartis Pharmaceuticals Corporation | $31.46 | 2024 | |
| Merck Sharp & Dohme LLC | $24.96 | 2025 | Welireg |
| Roche Diabetes Care, INC. | $24.00 | 2023 | Accu-Chek Guide Me |
| Ultragenyx Pharmaceutical INC. | $23.21 | 2023 | |
| Horizon Therapeutics Plc | $22.85 | 2023 | Tepezza |
| Glaxosmithkline, LLC. | $18.91 | 2025 | Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $12.99 | 2023 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leighton Harned listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.